Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Lam Research | 4.63% | $106.63M | $299.82B | 184.72% | 77 Outperform | |
| Newmont Mining | 3.56% | $82.02M | $136.07B | 169.42% | 81 Outperform | |
| Onto Innovation | 3.04% | $70.02M | $10.78B | 35.71% | 82 Outperform | |
| Southern Copper | 2.79% | $64.27M | $159.15B | 124.46% | 73 Outperform | |
| Medpace Holdings | 2.68% | $61.87M | $12.66B | 33.38% | 79 Outperform | |
| KLA | 2.56% | $58.92M | $194.03B | 98.33% | 77 Outperform | |
| Regeneron | 2.41% | $55.57M | $83.73B | 11.33% | 78 Outperform | |
| Jazz Pharmaceuticals | 2.32% | $53.44M | $10.25B | 26.60% | 64 Neutral | |
| Incyte | 2.23% | $51.41M | $20.50B | 40.51% | 81 Outperform | |
| Astera Labs, Inc. | 2.13% | $49.09M | $21.89B | 51.28% | 68 Neutral |